安捷伦科技宣布，其PD-L1 IHC 22C3 pharmDx检测试剂已获得美国食品药品监督管理局（FDA）的批准，可用于上皮性卵巢癌、输卵管癌或原发性腹膜癌（EOC）的诊断。这一重要进展将为相关癌症患者的精准治疗提供新的检测依据。
安捷伦科技宣布，其PD-L1 IHC 22C3 pharmDx检测试剂已获得美国食品药品监督管理局（FDA）的批准，可用于上皮性卵巢癌、输卵管癌或原发性腹膜癌（EOC）的诊断。这一重要进展将为相关癌症患者的精准治疗提供新的检测依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.